However, increased GLB1 levels lead to increased survival without prostate-specific antigen (PSA) in prostate cancer [59], which is contradictory with our outcomes, as well as the specific roles of GLB1 in glioma need to be further explored. This evidence concerns the gene GLB1 and prostate carcinoma.